BOTOX + Placebo

Phase 3Terminated

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Episodic Migraine

Conditions

Episodic Migraine

Trial Timeline

Nov 5, 2021 → Nov 6, 2024

NCT ID

NCT05028569

About BOTOX + Placebo

BOTOX + Placebo is a phase 3 stage product being developed by AbbVie for Episodic Migraine. The current trial status is terminated. This product is registered under clinical trial identifier NCT05028569. Target conditions include Episodic Migraine.

What happened to similar drugs?

3 of 15 similar drugs in Episodic Migraine were approved

Approved (3) Terminated (0) Active (12)

🔄DFN-11Dr. Reddy's LaboratoriesPhase 3

🔄GalcanezumabEli LillyPhase 3

🔄Galcanezumab + PlaceboEli LillyPhase 3

🔄Atogepant 60 mgAbbViePhase 3

✅Atogepant + UbrogepantAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06399718	Phase 3	Completed	Apr 30, 2024	Nov 10, 2025	Masseter Muscle Prominence
NCT06387394	Phase 3	Completed	Apr 22, 2024	Nov 25, 2025	Masseter Muscle Prominence
NCT06174688	Phase 3	Completed	Dec 12, 2023	Sep 13, 2024	Forehead Lines
NCT06068855	Phase 3	Completed	Oct 17, 2023	Nov 20, 2025	Masseter Muscle Prominence
NCT05028569	Phase 3	Terminated	Nov 5, 2021	Nov 6, 2024	Episodic Migraine

Competing Products

19 competing products in Episodic Migraine

See all competitors

Product	Company	Stage	Hype Score
DFN-11	Dr. Reddy's Laboratories	Phase 3	37
Galcanezumab	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	44
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Atogepant 60 mg	AbbVie	Phase 3	40
Atogepant + Ubrogepant	AbbVie	Approved	43
Atogepant + Placebo-Matching Atogepant	AbbVie	Phase 3	47
SOM230 + Placebo	Novartis	Phase 2	27
AMG334 + Oral Prophylactic	Novartis	Approved	43
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)	Novartis	Phase 3	40
Erenumab	Novartis	Phase 3	40
Placebo + AMG 301	Amgen	Phase 2	35
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)	Pfizer	Phase 1	29
Eptinezumab + Placebo	Lundbeck	Phase 3	44
Eptinezumab + Placebo	Lundbeck	Phase 3	37
Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A	Ipsen	Phase 3	41
IPN10200 + IPN10200 dose A + IPN10200 dose B	Ipsen	Phase 2	39
Methylprednisolone	Brain Biotech	Approved	33